NCT00935883: Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) |
|
|
| Completed | 2 | 60 | US | Eculizumab, Soliris, Saline, PBS | Philip J. Rosenfeld, MD, PhD, Alexion Pharmaceuticals | Age-Related Macular Degeneration | 06/12 | 08/13 | | |
NCT00904826: An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica |
|
|
| Completed | 1/2 | 14 | US | Eculizumab, Soliris | Mayo Clinic, Alexion Pharmaceuticals | Neuromyelitis Optica, Devic's Disease | 12/11 | 12/11 | | |
